Table 7 |
||||
|
Clinicopathological parameters in relation to EDN3 promoter methylation |
||||
|
Variables |
EDN3 promoter |
|||
|
|
||||
|
Numbera |
Unmethylated (percentage) |
Methylated (percentage) |
P valueb |
|
|
|
||||
|
Total |
128 |
39 (30.5) |
89 (69.5) |
|
|
Clinicopathological factors |
||||
|
Age at diagnosis |
||||
|
≤ 59 years |
64 |
22 (34) |
42 (66) |
0.443 |
|
> 59 years |
64 |
17 (29) |
47 (71) |
|
|
Tumour sizec |
||||
|
pT1 |
44 |
15 (34) |
29 (66) |
0.680 |
|
pT2 to pT4 |
72 |
21 (29) |
51 (71) |
|
|
Lymph node statusc |
||||
|
pN0 |
57 |
16 (28) |
41 (72) |
0.676 |
|
pN1 to pN3 |
51 |
17 (33) |
34 (67) |
|
|
Histological grade |
||||
|
G1 and G2 |
68 |
18 (26) |
50 (74) |
0.310 |
|
G3 |
49 |
18 (37) |
31 (63) |
|
|
Histological type |
||||
|
Ductal |
103 |
32 (31) |
71 (69) |
0.849 |
|
Lobular |
15 |
5 (33) |
10 (67) |
|
|
Other |
6 |
1 (17) |
5 (83) |
|
|
Immunohistochemistry |
||||
|
Oestrogen receptor |
||||
|
Negative (IRSd ≤ 2) |
33 |
11 (33) |
22 (67) |
0.655 |
|
Positive (IRS > 2) |
85 |
24 (28) |
61 (72) |
|
|
Progesterone receptor |
||||
|
Negative (IRSd ≤ 2) |
33 |
11 (33) |
22 (67) |
0.655 |
|
Positive (IRS > 2) |
85 |
24 (28) |
61 (72) |
|
|
|
||||
|
aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19]. dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3. |
||||
|
Wiesmann et al. Breast Cancer Research 2009 11:R34 doi:10.1186/bcr2319 |
||||
